Your browser is old and is not supported. Upgrade for better security.

InnaMed (YC W17)

Using at-home blood testing technology to enable personalized medicine

Pitch Video
Investor Panel

Investor Panel

Shu interviewed InnaMed (YC W17) on March 8, 2021. Play Video
Shu Li
CEO and co-founder of Petri-Bio
Strengths
says, "I'm very impressed by their extensive experience in the research field and deep understanding of the market. Different from many other biotech companies InnaMed has its unique business model and the potential to generate pre-regulation revenue, their patent portfolio is also very solid."
Advice
says, "As an investor I'd like to see more information about the future product pipeline of the company."

What Investors Say

Medical Director, Cone Health
LEAD INVESTOR
Invested $25,000 this round + $25,000 previously
Being able to monitor labs at home will allow physicians to close the loop with virtual care visits and provide safer and more guideline-driven therapy for our patients. The InnaMed HomeLab technology is the best I have seen. It is easy to use for the patient and will instantly raise the standard of care across numerous disease states. I'm investing because it is the piece we are missing to make our telemedicine visits even more meaningful.
What People Say